Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
John Sheppard,1 Mark Bergmann,2 Barry A Schechter,3 Jodi Luchs,4 Abayomi Ogundele,5 Paul Karpecki6 1Virginia Eye Consultants, Norfolk, VA, USA; 2Apex Eye, Cincinnati, OH, USA; 3Florida Eye Microsurgical Institute, Boynton Beach, FL, USA; 4Florida Vision Institute, West Palm Beach, FL, USA; 5Medical...
Saved in:
Main Authors: | Sheppard J, Bergmann M, Schechter BA, Luchs J, Ogundele A, Karpecki P |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/7c61de30f2d9482f8655c45512caa9dd |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
by: Periman LM, et al.
Published: (2020) -
A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca
by: Jerkins GW, et al.
Published: (2020) -
Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
by: de Oliveira RC, et al.
Published: (2019) -
Dry Eye Syndrome and Sicca Complex are Commonly Found in Patients with Postural Orthostatic Tachycardia Syndrome
by: Ho DS, et al.
Published: (2020) -
Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis
by: Groß D, et al.
Published: (2017)